ATE218879T1 - Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte - Google Patents

Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte

Info

Publication number
ATE218879T1
ATE218879T1 AT95913668T AT95913668T ATE218879T1 AT E218879 T1 ATE218879 T1 AT E218879T1 AT 95913668 T AT95913668 T AT 95913668T AT 95913668 T AT95913668 T AT 95913668T AT E218879 T1 ATE218879 T1 AT E218879T1
Authority
AT
Austria
Prior art keywords
bactericidal
permeability
therapeutic uses
increasing protein
protein dimer
Prior art date
Application number
AT95913668T
Other languages
English (en)
Inventor
William Steve Ammons
Roger G Little
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE218879T1 publication Critical patent/ATE218879T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95913668T 1994-03-11 1995-03-13 Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte ATE218879T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/212,132 US5447913A (en) 1994-03-11 1994-03-11 Therapeutic uses of bactericidal/permeability-increasing protein dimer products
PCT/US1995/003125 WO1995024209A1 (en) 1994-03-11 1995-03-13 Therapeutic uses of bactericidal/permeability-increasing protein dimer products

Publications (1)

Publication Number Publication Date
ATE218879T1 true ATE218879T1 (de) 2002-06-15

Family

ID=22789691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913668T ATE218879T1 (de) 1994-03-11 1995-03-13 Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte

Country Status (11)

Country Link
US (4) US5447913A (de)
EP (1) EP0749317B1 (de)
JP (1) JPH09510217A (de)
AT (1) ATE218879T1 (de)
AU (1) AU703134B2 (de)
CA (1) CA2185155C (de)
DE (1) DE69527049T2 (de)
DK (1) DK0749317T3 (de)
ES (1) ES2180629T3 (de)
PT (1) PT749317E (de)
WO (1) WO1995024209A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
JP2000501386A (ja) * 1995-11-14 2000-02-08 ゾーマ コーポレイション 角膜損傷に関連する病態を処置するための、殺菌性／透過性増強（ｂｐｉ）タンパク質
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
PT914144E (pt) * 1996-05-10 2001-05-31 Univ Texas Utilizacoes terapeuticas de produtos de proteinas bip contra a meningococcemia humana
CA2255539C (en) * 1996-05-23 2005-09-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
JP2000511892A (ja) * 1996-05-24 2000-09-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 可溶性ベーターシート形成性ペプチドの合成
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
WO1998019694A1 (en) * 1996-11-01 1998-05-14 Xoma Corporation Therapeutic uses of bpi protein products in cystic fibrosis patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20050159343A1 (en) * 1999-03-26 2005-07-21 Board Of Regents, University Of Texas System Inhibitors of glycosaminoglycans
WO2001003724A1 (en) * 1999-07-12 2001-01-18 Xoma Technology Ltd. Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity
ATE316097T1 (de) * 2000-01-20 2006-02-15 Univ Minnesota Peptide mit antibakterieller wirkung
US6686180B2 (en) * 2000-04-04 2004-02-03 Baxter International Inc. Method for the production of bacterial toxins
AU2002241589B2 (en) * 2000-12-01 2007-07-19 Xoma Technology Ltd. Modulation of pericyte proliferation using BPI protein products or BPI inhibitors
CA2476427A1 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
DK1492874T3 (da) 2002-03-29 2011-03-14 Xoma Technology Ltd Multigene vektorplasmider og fremgangsmåder til forøgelse af ekspressionen af rekombinante polypeptider
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
BRPI0916323A2 (pt) * 2008-07-21 2018-05-29 Otonomy Inc composições antimicrobianas de liberação controlada e métodos para o tratamento de distúrbios do ouvido
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
CN117686438B (zh) * 2024-02-02 2024-05-10 东北大学秦皇岛分校 一种基于红外偏振光的远程材料鉴别方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
AU669723B2 (en) * 1992-05-19 1996-06-20 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
ES2123134T3 (es) * 1993-03-12 1999-01-01 Xoma Corp Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
EP0690721B1 (de) * 1993-03-12 1998-05-13 Xoma Corporation Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE202482T1 (de) * 1993-03-12 2001-07-15 Xoma Technology Ltd Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
EP0759774B1 (de) * 1993-09-22 2002-06-12 XOMA Technology Ltd. Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
CA2173611C (en) * 1993-10-05 2005-07-26 Paul A. M. Van Leeuwen Method of treating depressed reticuloendothelial system function
WO1995019180A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries

Also Published As

Publication number Publication date
US6277821B1 (en) 2001-08-21
EP0749317A1 (de) 1996-12-27
US5447913A (en) 1995-09-05
CA2185155A1 (en) 1995-09-14
EP0749317B1 (de) 2002-06-12
DE69527049D1 (de) 2002-07-18
US5856302A (en) 1999-01-05
CA2185155C (en) 2001-08-14
PT749317E (pt) 2002-11-29
DE69527049T2 (de) 2003-03-06
AU1996995A (en) 1995-09-25
AU703134B2 (en) 1999-03-18
DK0749317T3 (da) 2002-10-07
ES2180629T3 (es) 2003-02-16
JPH09510217A (ja) 1997-10-14
US5703038A (en) 1997-12-30
WO1995024209A1 (en) 1995-09-14
HK1014159A1 (en) 1999-09-24

Similar Documents

Publication Publication Date Title
DE69527049D1 (de) Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
ATE273689T1 (de) Duftstoffvorläufer
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
NO20031159D0 (no) Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner
BR9403783A (pt) Uso de uma composição cosmética
HU214593B (hu) Kozmetikai, higiéniai, valamint szépség- és testápoló készítmények és eljárás azok előállítására
SE9804614D0 (sv) New peptides and use thereof
ATE179211T1 (de) Menschliche il-3-varianten
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
FR2755965B1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE69718047D1 (de) Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose
ATE218856T1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
FR2754818B1 (fr) Nouveaux derives bi-aromatiques du dibenzofuranne et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique
DE60036199D1 (de) Proteaseresistente flint-analoge
DE69334087D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
PT1429716E (pt) Preparacao cosmetica com accao anti-rugas
DE69323191D1 (de) Wasserlösliche retinoide
ES2056033T1 (es) Utilizacion de dl-valina y/o esteres de dl-valina y/o sales de dl-valina para combatir el aspecto grasiento del cabello y la piel.
ES2067058T3 (es) Tratamiento de carnes.
ES2054599T3 (es) Utilizacion cosmetica de dl-valina, sus esteres y/o sales para combatir la caspa.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee